மருத்துவ ஆராய்ச்சி செயல்பாடுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மருத்துவ ஆராய்ச்சி செயல்பாடுகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மருத்துவ ஆராய்ச்சி செயல்பாடுகள் Today - Breaking & Trending Today

Clinical Research Operations Manager

Clinical Research Operations Manager
Planned Parenthood Southeastern Pennsylvania is the local affiliate of the country’s leading sexual and reproductive health care advocate and provider. Planned Parenthood Southeastern Pennsylvania (PPSP) operates 10 health centers throughout Chester, Delaware, Montgomery, and Philadelphia counties. Nationwide, Planned Parenthood affiliates operate more than 600 health centers, providing medical services and sexuality education for millions of individuals (adults and teens) each year. We also work with allies worldwide to ensure that all people have the right and the means to meet their sexual and reproductive health care needs.
If you are passionate about reproductive health and the opportunity to contribute in a mission-drive environment, consider joining PPSP as Clinical Research Operations Manager. This is a benefits-eligible, full-time, 35 hour/week position responsible to oversee the day-to-day operations of all clinical rese ....

United States , Clinical Research Operations Manager , Planned Parenthood Southeastern Pennsylvania , Planned Parenthood , Clinical Research Operations , Parenthood Southeastern Pennsylvania , ஒன்றுபட்டது மாநிலங்களில் , திட்டமிடப்பட்டுள்ளது பெற்றோர்நிலை தென்கிழக்கு பென்சில்வேனியா , திட்டமிடப்பட்டுள்ளது பெற்றோர்நிலை , மருத்துவ ஆராய்ச்சி செயல்பாடுகள் , பெற்றோர்நிலை தென்கிழக்கு பென்சில்வேனியா ,

Wesana Health Closes $4 Million Convertible Note Round

Wesana Health Closes $4 Million Convertible Note Round
News provided by
Share this article
New additions to senior management and leadership teams
CHICAGO, Jan. 21, 2021 /PRNewswire/ Wesana Health, an emerging life sciences company committed to patient empowerment and the advancement of psilocybin-based medicine to improve health and wellness, has announced the close of a $4 million convertible note financing round. The company also announced new additions to its senior leadership team.
Wesana Health Raises Funds to Enter the Psychedelics Space
The $4 million round, led by The Conscious Fund and Ambria Capital, LLC, provides funding to support the Company s entry into the emerging psychedelics space. The proceeds will allow Wesana to begin preclinical and clinical work on the use of psychedelic-assisted therapy to treat traumatic brain injury (TBI) as well as regulatory applications including Investigational New Drug (IND) filings with the Food and Drug ....

United States , Mitch Kahn , Henri Sant Cassia , Daniel Carcillo , Cody Shandraw , Curaleaf Holdings , Conscious Fund , Company Board Of Directors , Drug Administration , Research Team In Late , Founder Of Wesana Health , Wesana Health , Stage Development At Biogen , Health Canada , Research Operations , Cambria Capital , Health Raises Funds , Investigational New Drug , Investigational Medicinal Product Dossier , Stanley Cup Championships , Chicago Blackhawks , Heroic Hearts Project , Founding Partner , Senior Management , Chad Bronstein , Executive Chairman ,

Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM). Results from the I-RUX Study Published in ASH2020

Share this article
Share this article
WEST HOLLYWOOD, Calif., Jan. 20, 2021 /PRNewswire/ ONCOtherapeutics and Dr. James Berenson published promising new data demonstrating that ruxolitinib (RUX), an oral JAK1/2 inhibitor, with only steroids is well tolerated and shows promising efficacy for treating heavily previously treated MM patients.
Recently published results from a Phase 1 trial for 28 heavily previously treated MM patients administered RUX, LEN and methylprednisolone (MP) demonstrated that the therapy was well tolerated and RUX overcame refractoriness to LEN and steroids (Berenson
et al.,
Clin Cancer Res. 2020). The clinical and overall response rates were 46% and 28%, respectively, and all 12 responding patients were refractory to LEN. ....

Jamesr Berenson , Armandoj Sanchez , James Berenson , Contract Research Organization , Clinical Research Operations , Clin Cancer , West Hollywood Based , Key Opinion Leaders , ஜேம்ஸ் பெரன்சன் , ஒப்பந்த ஆராய்ச்சி ஆர்கநைஸேஶந் , மருத்துவ ஆராய்ச்சி செயல்பாடுகள் , கிளினிக் புற்றுநோய் , மேற்கு ஹாலிவுட் அடிப்படையிலானது , விசை கருத்து தலைவர்கள் ,